Efor Expands North American Presence by Acquiring DynamixE for Enhanced Life Sciences Solutions

Efor Solidifies North American Expansion with Acquisition of DynamixE

In a significant move within the Life Sciences sector, Efor, a French leader in quality and compliance, announces the acquisition of U.S.-based DynamixE, Inc. This strategic acquisition, unveiled on March 2, 2026, allows Efor to bolster its presence in North America and enhance its capabilities in Commissioning, Qualification & Validation (CQV) and process engineering solutions. Founded in 2013, Efor has developed a global workforce of over 3,000 professionals, generating nearly $60 million in U.S. revenue, which forms part of a total of about $400 million across its global operations.

DynamixE, established in 2017, is renowned for its expertise in CQV and advanced process engineering, with a focus on biologics and cell and gene therapy biomanufacturing. The company operates in critical life sciences hubs across the United States, including North Carolina, Massachusetts, and California. The acquisition marks Efor's strategic efforts to deepen its operational footprint in North America, a region characterized by increasing demands for comprehensive quality and compliance solutions. Mathieu Roger, Efor's Founder and President, highlights that this acquisition not only enhances Efor's operational alignment with DynamixE but also strengthens delivery standards across shared projects.

Integrating DynamixE into its operations enables Efor to address the complexities of the growing Life Sciences industry more effectively. The companies have previously collaborated on multiple large-scale projects, creating a solid foundation for this integration and promising to elevate Efor's existing service offerings in CQV. Kartik Subramanian, DynamixE's Founder and CEO, affirms that this relationship will extend their market reach while maintaining a steadfast commitment to excellence in biomanufacturing. With this move, Efor continues to position itself as a formidable player in the Life Sciences sector, aligning with its ongoing growth strategy focused on targeted acquisitions.

In addition to its pursuits in North America, Efor has also expanded its operations in Asia through the acquisition of Singapore-based No deviation, a firm specializing in CQV and Quality Compliance. This partnership not only enhances Efor's capabilities in the rapidly evolving biopharmaceutical sector but also fortifies its strategic presence in the Asia-Pacific region. With an emphasis on delivering high-value compliance solutions for complex projects, Efor underscores its global vision of leadership in the Life Sciences industry, combining organic growth with strategic investments.

As Efor broadens its global footprint, this dual focus on North American and Asian markets demonstrates a commitment to addressing the increasing complexities and demands inherent in the Life Sciences industry, solidifying its reputation as a leader in quality and compliance solutions.